Banoth Bhaskar, Verma Anjali, Bhalla Kapil, Khanna Alok, Holla Saraswathi, Yadav Swati
Department of Pediatrics, PGIMS, Rohtak, Haryana, India.
J Family Med Prim Care. 2022 Apr;11(4):1395-1400. doi: 10.4103/jfmpc.jfmpc_1210_21. Epub 2022 Mar 18.
Acute exacerbation of asthma is a common condition leading to emergency visits. Prednisolone is a commonly prescribed drug in the standard management of acute exacerbation of asthma along with other drugs. This study was planned to see the efficacy of oral dexamethasone when compared with oral prednisolone in the management of acute exacerbation of asthma.
A single-center pilot study in the form of randomized control trial was done by recruiting children aged 2-14 years diagnosed with acute asthma exacerbation with mild to moderate severity. A total of 88 patients received oral dexamethasone (0.3 mg/kg) in two doses 24 h apart, which was compared with 87 patients who received oral prednisolone (1 mg/kg) in two divided doses 12 h apart for 5 days. The patients were assessed at the time of admission (zero hour), at 4 hour, and on the 5 day by various parameters such as respiratory rate, use of accessory muscles, Pediatric Respiratory Assessment Measure (PRAM) score, peak expiratory flow rate (PEFR), 6-h admission stay, and rate of hospital admission.
Baseline demographic profile, clinical characteristics, comorbidities, indoor pollution, and use of Metered Dose Inhaler (MDI) among the two study groups were comparable. Six-hour emergency stay and rate of admission were significantly lower in the dexamethasone group ( < 0.05). Improvement in PRAM score, PEFR, use of accessory muscles, and respiratory rate was also better in dexamethasone group at the 4 hour and 5 day ( < 0.05). In addition, oral dexamethasone was shown to have less incidence of vomiting/gastritis than prednisolone ( < 0.05).
Oral dexamethasone can be considered a reliable and better option as compared with prednisolone due to its faster action and minimal side effects.
哮喘急性加重是导致急诊就诊的常见病症。泼尼松龙是哮喘急性加重标准治疗中与其他药物一起常用的处方药。本研究旨在观察口服地塞米松与口服泼尼松龙相比在哮喘急性加重治疗中的疗效。
以随机对照试验形式进行的单中心试点研究,招募了2至14岁被诊断为轻度至中度急性哮喘加重的儿童。总共88例患者接受口服地塞米松(0.3mg/kg),分两剂,间隔24小时,与87例接受口服泼尼松龙(1mg/kg),分两剂,间隔12小时,共5天的患者进行比较。在入院时(零小时)、4小时和第5天通过各种参数对患者进行评估,如呼吸频率、辅助肌使用情况、儿科呼吸评估量表(PRAM)评分、呼气峰值流速(PEFR)、6小时住院时间和住院率。
两个研究组的基线人口统计学特征、临床特征、合并症、室内污染和定量吸入器(MDI)的使用情况具有可比性。地塞米松组的6小时急诊住院时间和住院率显著更低(<0.05)。在4小时和第5天,地塞米松组的PRAM评分、PEFR、辅助肌使用情况和呼吸频率的改善也更好(<0.05)。此外,口服地塞米松的呕吐/胃炎发生率低于泼尼松龙(<0.05)。
与泼尼松龙相比,口服地塞米松因其作用更快且副作用最小,可被视为一种可靠且更好的选择。